NCT02825836 - Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

August 26, 2016

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2025

Conditions

Relapsed/Refractory B Cell MalignanciesMantle Cell Lymphoma and Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaTreatment-Naive B Cell Malignancies

Interventions

DRUG

TL-895

TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

DRUG

Navtemadlin

Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.

Trial Locations (17)

3300

Eger Markhot Ferenc Kórház, Eger

4002

Debreceni Egyetem - Borgyógyászati Klinika, Debrecen

38138

The West Clinic, Germantown

40138

Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi - Istituto di Ematologia e Oncologia Medica, Bologna

43210

Ohio State University Wexner Medical Center, Columbus

54058

Mykolaiv Regional Clinical Hospital, Mykolaiv

61000

Communal Non-profit Enterprise Regional Center of Oncology, Kharkiv

150023

Yaroslavl Regional Clinical Hospital, Yaroslavl

197022

Saint Petersburg State Medical University, Saint Petersburg

60-185

Examen sp. z o. o., Skorzewo

30-510

Pratia MCM Krakow, Krakow

20-090

Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli Oddzial Hematologiczny, Lublin

46-020

Szpital Wojewódzki, Opole

87-100

Nasz Lekarz Przychodnie Medyczne, Torun

03110

Kyiv City Clinical Hospital #4, Kyiv

Unknown

University College London Hospitals - NIHR/Wellcome Trust, London

Derriford Hospital - Dept of Haematology, Plymouth

All Listed Sponsors

lead

Telios Pharma, Inc.

INDUSTRY